Munson Healthcare expands COVID-19 Infusion Treatment


Munson Healthcare is offering an infusion treatment called monoclonal antibody therapy for treating patients with mild or moderate COVID-19 symptoms. 

This one-time outpatient infusion therapy may help patients recover quicker and avoid hospitalization. The treatment is especially useful for patients with conditions that put them at higher risk of developing a more severe form of the disease. Previously requiring a physician’s order, patients can now self-refer for this treatment by contacting Munson Healthcare’s Ask-A-Nurse line at 231-935-0951.

Monoclonal antibodies are lab-produced molecules that can mimic the immune system’s ability to fight viruses and other harmful pathogens. This outpatient infusion therapy targets different parts of the COVID-19 virus and prevents it from bonding with cells in the body. The FDA has authorized the use of monoclonal antibodies for the treatment of COVID-19 under an Emergency Use Authorization (EUA).

Patients who test positive for COVID-19 may qualify for the treatment. Therapy must be administered within 10 days of the onset of symptoms.  Patients must be at least 12 years old and weigh at least 88 pounds. Monoclonal antibody therapy is offered at Munson Healthcare locations in Traverse City, Kalkaska, Grayling, and Cadillac. Limited in-home treatment may also be available. 

Monoclonal antibody therapy is covered by most health insurance policies. COVID-19 positive patients should call their primary care provider or Munson Healthcare Ask-A-Nurse at 231-935-0951 to discuss this treatment option. The Ask-A-Nurse service is available daily from 7 a.m. – 11 p.m. at no charge. For additional details visit